The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Predictive factors for early mortality after initiation of regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer.
 
Toshiki Masuishi
Honoraria - Bayer Yakuhin; Chugai Pharma; Lilly; Merck Serono; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Yakult Honsha
 
Toshikazu Moriwaki
Speakers' Bureau - Chugai Pharma; Merck Serono; Novelpharm; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Boehringer Ingelheim (Inst); Eisai (Inst); MSD (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
 
Shota Fukuoka
Research Funding - Bayer (Inst); MSD (Inst); Ono Pharmaceutical (Inst)
 
Atsuo Takashima
Honoraria - Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - LSK BioPharma; Sumitomo Group; Takeda
 
Yosuke Kumekawa
No Relationships to Disclose
 
Takeshi Kajiwara
Honoraria - Chugai Pharma; Kyowa Hakko Kirin; Medical & Biological Laboratories; Merck Serono; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Medical & Biological Laboratories (Inst); Sanofi (Inst)
 
Kentaro Yamazaki
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Taiho Pharmaceutical (Inst)
 
Taito Esaki
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly; Merck Serono; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb Japan (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst)
 
Akitaka Makiyama
Speakers' Bureau - Chugai Pharma; Lilly; Takeda
 
Tadamichi Denda
Speakers' Bureau - Chugai Pharma; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Boehringer Ingelheim (Inst); MSD (Inst); Sanofi (Inst)
 
Hironaga Satake
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck Serono; MSD; Ono pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Takeshi Suto
No Relationships to Disclose
 
Naotoshi Sugimoto
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly Japan (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Kenji Katsumata
No Relationships to Disclose
 
Toshiaki Ishikawa
Honoraria - Chugai Pharma; Daiichi Sankyo; Sanofi; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Takeda
 
Tomomi Kashiwada
Speakers' Bureau - Chugai Pharma; Lilly Japan; Merck Serono; Taiho Pharmaceutical
 
Eiji Oki
Speakers' Bureau - Bayer Yakuhin; Chugai Pharma; Lilly Japan; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Yoshito Komatsu
Honoraria - Bayer; Novartis; Pfizer
Speakers' Bureau - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; Nipro Corporation; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Taiho Pharmaceutical; Takeda; TOWA; Yakult Honsha
Research Funding - Astellas Pharma; Bayer; Boehringer Ingelheim; Chugai Pharma; Dainippon Sumitomo Pharma; Eisai; Lilly; MSD; Novartis; Ono Pharmaceutical; Sanofi; Sysmex; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
 
Kenichi Yoshimura
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Eisai; Lilly; Taiho Pharmaceutical; Takeda
 
Yasuhiro Shimada
Honoraria - AstraZeneca; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Merck Serono; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; TAKEDA; Tsumura & Co.; Yakult Honsha
Research Funding - Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD K.K (Inst); Taiho Pharmaceutical (Inst)